Could a vaccine finally stop the common cold?
NCT ID NCT07399132
First seen Feb 13, 2026 · Last updated May 24, 2026 · Updated 17 times
Summary
This early-phase study tests a new vaccine (APL-10456) designed to protect against rhinovirus, the main cause of the common cold. About 144 healthy volunteers, split into younger (18-54) and older (55+) groups, will receive either the vaccine or a placebo. Researchers will monitor safety, side effects, and immune response to see if the vaccine triggers protective antibodies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHINOVIRUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emeritus Research
RECRUITINGMelbourne, Victoria, 3124, Australia
-
Veritus Research
RECRUITINGMelbourne, Victoria, 3153, Australia
Conditions
Explore the condition pages connected to this study.